JAC Advance Access published online on December 5, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl455
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Virology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
* To whom correspondence should be addressed. Background: Current hepatitis C virus (HCV) therapies may cure Methods: Binding constant of SCH446211 to HCV NS3 protease was measured with the chromogenic substrate in vitro cleavage assay. Cell-based activity of SCH446211 was evaluated in replicon cells, which are Huh-7 hepatoma cells stably transfected with a subgenomic HCV RNA as reported previously. After 72 h of incubation with SCH446211, viral transcription and protein expression were measured by real-time RT-PCR (TaqMan), quantitative in situ hybridization, immunoblot and indirect immunofluorescence. Results: The binding constant of SCH446211 to HCV NS3 protease was 3.8 ± 0.4 nM. HCV replication and protein expression were inhibited by SCH446211 in replicon cells as consistently shown by four techniques. In particular, based on quantitative real-time RT-PCR measurements, the IC50 and IC90 of SCH446211 were estimated to be 40 ± 20 and 100 ± 20 nM (n = 17), respectively. Long-term culture of replicon cells with SCH446211 reduced replicon RNA to <0.1 copy per cell. SCH446211 did not show cellular toxicity at concentrations up to 50 µM. Conclusions: SCH446211 is a potent inhibitor of HCV protease in vitro. Its extended interaction with the HCV NS3 protease active site is associated with potent in vitro antiviral activity. This observation is potentially a useful guide for development of future potent inhibitors against HCV NS3 protease.
Received June 29, 2006
Revised September 15, 2006
Accepted October 4, 2006
Original article
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease
Rong Liu 1 *, Karim Abid 2, John Pichardo 1, Valerio Pazienza 3, Paul Ingravallo 1, Rong Kong 1, Sony Agrawal 1, Stephane Bogen 4, Anil Saksena 4, Kuo-Chi Cheng 5, Andrew Prongay 4, F. George Njoroge 4, Bahige M. Baroudy 1, and Francesco Negro 6
2 Divisions of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
3 Clinical Pathology, University Hospital, Geneva, Switzerland
4 Chemical Research, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
5 Drug Metabolism, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
6 Divisions of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland; Clinical Pathology, University Hospital, Geneva, Switzerland
Rong Liu, E-mail: Rong.Liu{at}spcorp.com
Abstract 
60% of infections. They are often contraindicated or poorly tolerated, underscoring the need for safer and more effective drugs. A novel, 
-ketoamide-derived, substrate-based inhibitor of the HCV serine protease (SCH446211) was developed. Compared with earlier reported inhibitors of similar chemical class, it has a P1'-P2' extension which provides extended interaction with the protease active site. The aim of this study was to evaluate the in vitro antiviral activity of SCH446211.
CiteULike 
Connotea 
Del.icio.us What's this?